Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H12O6 |
Molecular Weight | 180.1559 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO
InChI
InChIKey=BJHIKXHVCXFQLS-UYFOZJQFSA-N
InChI=1S/C6H12O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3,5-9,11-12H,1-2H2/t3-,5-,6-/m1/s1
Molecular Formula | C6H12O6 |
Molecular Weight | 180.1559 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://onlinelibrary.wiley.com/doi/10.1002/14356007.a12_047.pub2/abstract | https://www.ncbi.nlm.nih.gov/pubmed/12399260 | https://www.ncbi.nlm.nih.gov/pubmed/26567197 | https://www.ncbi.nlm.nih.gov/pubmed/26316589 | https://www.ncbi.nlm.nih.gov/pubmed/26856717 | https://www.ncbi.nlm.nih.gov/pubmed/23493541https://onlinelibrary.wiley.com/doi/abs/10.1002/adsc.200600356 |
http://onlinelibrary.wiley.com/doi/10.1002/14356007.a12_047.pub2/abstract |
https://www.ncbi.nlm.nih.gov/pubmed/26594441 |
https://books.google.ru/books?id=nZrwBwAAQBAJ&pg=PA59&lpg=PA59&dq=%22l-fructose%22&source=bl&ots=kAl43H3Ini&sig=ACfU3U3RmEF0Y1D8WrnNoe6kJdICbTywoQ&hl=en&sa=X&ved=2ahUKEwih49yMzL7hAhUlyaYKHa2JBNkQ6AEwEXoECDQQAQ#v=onepage&q=%22l-fructose%22%20sweetener&f=false
Sources: http://onlinelibrary.wiley.com/doi/10.1002/14356007.a12_047.pub2/abstract | https://www.ncbi.nlm.nih.gov/pubmed/12399260 | https://www.ncbi.nlm.nih.gov/pubmed/26567197 | https://www.ncbi.nlm.nih.gov/pubmed/26316589 | https://www.ncbi.nlm.nih.gov/pubmed/26856717 | https://www.ncbi.nlm.nih.gov/pubmed/23493541https://onlinelibrary.wiley.com/doi/abs/10.1002/adsc.200600356 |
http://onlinelibrary.wiley.com/doi/10.1002/14356007.a12_047.pub2/abstract |
https://www.ncbi.nlm.nih.gov/pubmed/26594441 |
https://books.google.ru/books?id=nZrwBwAAQBAJ&pg=PA59&lpg=PA59&dq=%22l-fructose%22&source=bl&ots=kAl43H3Ini&sig=ACfU3U3RmEF0Y1D8WrnNoe6kJdICbTywoQ&hl=en&sa=X&ved=2ahUKEwih49yMzL7hAhUlyaYKHa2JBNkQ6AEwEXoECDQQAQ#v=onepage&q=%22l-fructose%22%20sweetener&f=false
Fructose, or fruit sugar, is a simple ketonic monosaccharide found in many plants, where it is often bonded to glucose to form the disaccharide sucrose. In nature, fructose is produced as D-enantiomer. D-Fructose is one of the three dietary monosaccharides, along with glucose and galactose, that are absorbed directly into the bloodstream. L-fructose is an enantiomer of D-fructose. L-fructose does not occur naturally and can be produced synthetically from the racemic mixture of D- and L-fructose. L-fructose was investigated as a non-caloric sweetener; however it was detected that digestibility of L-fructose is 10% lower than D-fructose, and L-fructose did not found significant commercial application.
CNS Activity
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Fructose, weight gain, and the insulin resistance syndrome. | 2002 Nov |
|
Effects of fructose vs glucose on regional cerebral blood flow in brain regions involved with appetite and reward pathways. | 2013 Jan 2 |
|
Challenging the fructose hypothesis: new perspectives on fructose consumption and metabolism. | 2013 Mar 1 |
|
Uptake and metabolism of fructose by rat neocortical cells in vivo and by isolated nerve terminals in vitro. | 2015 May |
|
Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease. | 2016 May |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02590913
Twenty healthy volunteers were randomized into two groups: group A received 300 mL of 22.5% glucose and group B received 300 mL of 22.5% fructose. The solution was consumed after 8 hours of overnight fasting, the repeated with the opposite solution after a 1 week washout period. At each intervention venous blood was collected at 0, 0.5, 1, 2 and 3 hours, ad blood-pressure was recorded at 0, 1, 2, and 3 hours.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25708447
Nerve terminals were prepared from rat forebrains and purified synaptosomes were exposed to [U14C]fructose or [U14C]glucose for 10 minutes leading to the selective labeling of glutamate over aspartate and GABA, and Alanine. [U-14C]Fructose shoed a preference for labeling glutamate more strongly, and aspartate and GABA less strongly, than did [U-14C]glucose. Thus, the distribution of label between glutamate, aspartate, and GABA was significantly different in synaptosomes exposed to [U-14C]fructose or [U-14C]glucose, as reflected in an aspartate/glutamate labeling ratio of 0.07 and 0.53 and a GABA/glutamate labeling ratio of 0.03 and 0.36 for [U14C]fructose- and [U14C]glucose-exposed synaptosomes respectively. The increased labeling of glutamate indicates increased uptake of fructose into nerve terminals and oxidative fructose metabolism in these structures.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:38:49 GMT 2023
by
admin
on
Sat Dec 16 18:38:49 GMT 2023
|
Record UNII |
6YSS42VSEV
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
48432-9
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
||
|
LOINC |
51593-2
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
||
|
WHO-VATC |
QV06DC02
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
||
|
LOINC |
13943-6
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
||
|
LOINC |
2297-0
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
||
|
LOINC |
2296-2
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
||
|
WHO-ATC |
V06DC02
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
||
|
LOINC |
34309-5
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
||
|
LOINC |
34308-7
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
||
|
LOINC |
49772-7
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
||
|
DSLD |
1322 (Number of products:48)
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
||
|
FDA ORPHAN DRUG |
28188
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
||
|
LOINC |
2295-4
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
||
|
LOINC |
10574-2
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
||
|
LOINC |
32240-4
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
||
|
LOINC |
34307-9
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
||
|
NCI_THESAURUS |
C68479
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
||
|
LOINC |
56624-0
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
||
|
LOINC |
15070-6
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
||
|
LOINC |
34194-1
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
28757
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
48095
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
6347-01-9
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
ALTERNATIVE | |||
|
C68480
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
10489-79-9
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
ALTERNATIVE | |||
|
15824
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
FRUCTOSE
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
200-333-3
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
SUB126925
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
1252
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
760385
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
6YSS42VSEV
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
SUB13925MIG
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
28645
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
100000078511
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
5984
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL604608
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
6YSS42VSEV
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
4570
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | RxNorm | ||
|
37721
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
9250
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
m5572
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB04173
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
57-48-7
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
D005632
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY | |||
|
1286504
Created by
admin on Sat Dec 16 18:38:50 GMT 2023 , Edited by admin on Sat Dec 16 18:38:50 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SUB_CONCEPT->SUBSTANCE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |